Related Experiment Video

Updated: Aug 7, 2026

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

COOH-terminal Src kinase-mediated c-Jun phosphorylation promotes c-Jun degradation and inhibits cell transformation

Feng Zhu1, Bu Young Choi, Wei-Ya Ma

  • 1Hormel Institute, University of Minnesota, Austin, Minnesota, USA.

Cancer Research
|June 3, 2006
PubMed

Insights

The COOH-terminal Src kinase (CSK) promotes the degradation of the oncoprotein c-Jun, reducing cell transformation. This finding reveals CSK

Area of Science:

  • Molecular Biology
  • Cellular Biology
  • Oncology

Background:

  • The oncoprotein c-Jun, a component of the activator protein-1 (AP-1) transcription factor, is crucial for cellular proliferation, transformation, and death.
  • Stabilization of c-Jun is essential for its function, and its phosphorylation by c-Jun NH(2)-terminal kinase 1 (JNK1) and extracellular signal-regulated kinases (ERK) promotes stability by reducing ubiquitination.

Purpose of the Study:

  • To investigate the role of COOH-terminal Src kinase (CSK) in regulating c-Jun stability and function.
  • To elucidate the mechanism by which CSK affects c-Jun phosphorylation and degradation.

Main Methods:

  • Co-immunoprecipitation assays to demonstrate binding between CSK and c-Jun.
  • In vitro kinase assays to confirm phosphorylation of c-Jun by CSK at specific tyrosine residues (Y26 and Y170).
  • Western blotting and ubiquitination assays to assess c-Jun degradation and stability following CSK-mediated phosphorylation.

Main Results:

  • CSK directly binds to and phosphorylates c-Jun at tyrosine residues Y26 and Y170.
  • CSK-mediated phosphorylation of c-Jun promotes its degradation, contrasting with the stabilizing effect of JNK1 and ERK.
  • This degradation leads to reduced c-Jun stability, decreased activator protein-1 (AP-1) activity, and inhibition of c-Jun-induced cell transformation.

Conclusions:

  • CSK acts as a negative regulator of c-Jun stability and AP-1 activity by promoting c-Jun degradation.
  • CSK's function in controlling c-Jun levels is important for regulating cell proliferation under normal conditions.
  • Dysregulation or loss of CSK function may contribute to carcinogenesis by allowing elevated c-Jun levels and sustained cell transformation.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting10:08

Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

Published on: December 9, 2022

Related Concept Videos

Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...